NEW YORK (GenomeWeb News) – German genetic engineering company Gene Bridges said today that it has licensed its DNA recombination technology to Japanese pharmaceutical firm Daiichi Sankyo.
The company said that the technology, which is patented in Japan as a "Novel DNA Cloning Method," is used to generate targeting vectors or for modifying E. coli chromosomes.
The Heidelberg-based company's RedET technology allows cloning, subcloning, and DNA modification at chosen positions, and it enables engineering of large DNA molecules, such as BACs and E. coli.
Funakoshi serves as Gene Bridges' distribution partner in Japan.
Financial terms of the agreement were not released.